Summary of the Report and Recommendations of the Congressionally-Established Diabetes Research Working Group
A Strategic Plan for the 21st CenturyTransmittal to the Congress
In accordance with directives from the House and Senate Appropriations Committees, I am pleased to transmit to the Congress the summary of the Strategic Plan for NIH-funded diabetes research developed by the congressionally-established Diabetes Research Working Group.* As specified by the Congress, this Research Plan includes recommendations for future diabetes research directions and corresponding overall budget estimates for implementing the proposed new research initiatives.
The Diabetes Research Working Group is an independent panel composed of twelve scientific experts in diabetes and four representatives from the lay diabetes community. In developing its Strategic Research Plan, the Working Group held plenary meetings and subcommittee discussions, analyzed the existing NIH diabetes research portfolio, sought the expertise of ad hoc scientists, and enlisted public commentary. The Diabetes Research Working Group believes that the culmination of this year-long, in-depth planning process is a set of recommendations that will be of value to the Congress and to the NIH.
Clearly, the congressional action calling for the establishment of the Diabetes Research Working Group and the development of its Research Plan reflects the strong and continuing commitment of the Congress to conquering diabetes. The implementation of the research initiatives recommended in this Strategic Research Plan is the next vital step toward attaining that objective.
C. Ronald Kahn, M.D.
Diabetes Research Working Group
*Note: The congressional directives calling for the establishment of the Diabetes Research Working Group and the development of its Strategic Research Plan can be found in Senate Report 105-58 (1998, p. 76, p. 110), House Report 105-205 (1998 , p. 69, p. 98) and House Report 105-635 (1999, p. 69). The charge to the Diabetes Research Working Group called for the development of a comprehensive plan for all NIH-funded diabetes research efforts, including the recommendation of future diabetes research initiatives and directives. Congressional language specifically asked the Working Group to include overall cost estimates to accomplish its recommendations in the final research plan.
This Strategic Research Plan for diabetes research funded by the National Institutes of Health has been developed by an independent, congressionally-established Diabetes Research Working Group, with input from diabetes investigators, diabetes patients, and other members of the broad diabetes research community. The Working Group is composed of scientific and lay experts external to the National Institutes of Health, as well as leaders of major diabetes voluntary organizations. The views, conclusions, and recommendations expressed in this document are solely those of the members of the Diabetes Research Working Group and do not necessarily reflect the positions or judgments of the National Institutes of Health, the Department of Health and Human Services, or the Administration, which must weigh the competing requirements of multiple programs and activities. (NIH Publication No. 99-4398)
The photographs in this document are not available for republication and may not be reproduced in either print or electronic format without the express written consent and permission of the photographer.
Cover: Robert Reichert (Center), Mark Tuschman (Top right), American Diabetes Association, Honolulu (Lower left), Bristol-Myers Squibb (Lower right)
Page 4: Peter F. Kador, National Eye Institute
Sixteen million people in the United States have diabetes mellitus. In both human and economic terms, it is one of our nation’s most costly diseases. Diabetes is the leading cause of kidney failure, blindness in adults, and amputations. It is a major risk factor for heart disease, stroke, and birth defects, shortens average life expectancy by up to 15 years, and costs the nation in excess of $100 billion annually in health-related expenditures. At present, more than one of every ten health-care dollars and about one of every four Medicare dollars are spent on people with diabetes. Over the next decade these numbers will grow as the number of people afflicted by diabetes continues to increase at an accelerating rate. At present, there is no method to prevent or cure diabetes, and available treatments have only limited success in controlling its devastating consequences. This problem is made more complex by the fact that diabetes mellitus is not a single disease, but occurs in several forms, and has complications that affect virtually every system of the body. The most common forms are Type 1 (insulin-dependent) diabetes, which usually starts in childhood or adolescence, and Type 2 (non-insulin dependent) diabetes, which typically affects adults and increases dramatically with age and obesity.
Congress has clearly recognized the gravity of diabetes through the establishment of a bipartisan Diabetes Caucus and has concluded that the only way to reduce the tremendous burden of this disease is through intensified biomedical research. Over the past three years, Congress has emphasized diabetes research in funding increases provided to the NIH and through other special initiatives. Realizing the critical need to build upon these important steps, the Congress directed the establishment of the Diabetes Research Working Group (DRWG) and charged it with developing a comprehensive plan for diabetes research. This plan is intended to help increase the effectiveness of NIH-funded diabetes research and find solutions to the extremely serious problems posed by this disease. During 1998, the DRWG and its subcommittees held a series of meetings, consulted with a wide range of experts in the field, and heard public commentary. It evaluated all aspects of the diabetes problem in an effort to develop a comprehensive plan for submission to the Congress. This document summarizes the Strategic Research Plan of the Diabetes Research Working Group.
Based on its extensive review and deliberations, the DRWG recognizes both great urgency and unprecedented opportunities in diabetes research. The seriousness of the disease and the widespread problems associated with it demand accelerated and expanded research programs, not only to discover the means to prevent and cure diabetes, but also to develop better and more effective treatment strategies. Meeting these challenges requires a well-thought-out and continuously updated research plan; a cadre of talented researchers and physician-scientists; a supportive infrastructure; and appropriate budgetary resources. The DRWG is convinced that taking action now to increase significantly NIH support of diabetes research will save many thousands of men, women and children from the severe consequences of a dangerous, often disabling and potentially even fatal illness, and will also save the nation many billions of dollars in medical care and lost productivity. From both human and scientific perspectives, now is the time for the United States to move swiftly and decisively to begin to ensure a future for America without diabetes.
The Federal Investment in Diabetes ResearchReducing the tremendous health and human burden of diabetes and its enormous economic toll depends upon identifying the factors responsible for the disease and developing new methods for treatment and prevention. These advances can only occur through increased biomedical research. Although Federal support for diabetes research has produced a number of major advances in the past two decades, many scientific opportunities are not being pursued due to insufficient funding, lack of appropriate mechanisms, and a shortage of trained researchers. Improvements in technology and the general growth in scientific knowledge offer unprecedented opportunities for advances that might lead to better treatments, prevention and possibly cure. Unfortunately, the current funding, level of effort, and scope of diabetes research fall far short of what is needed to capitalize on these opportunities.
The U.S. Government, through the National Institutes of Health (NIH), will spend an estimated $443 million in FY 1999 on diabetes-related research. While this amount has steadily increased since 1981, there is unanimous agreement in the DRWG that this funding level is far short of what is required to make progress on this complex and difficult problem. In fact, the current federal budget for diabetes research represents less than one-half of one percent (0.5 percent) of the annual cost of diabetes to the U.S. economy. When compared with the 5 to 15 percent budgets for research and development in other high-technology sectors, the investment in diabetes research is trivial.
Meeting the challenges posed by diabetes requires investment of additional resources to conduct the needed research and a well-conceived, comprehensive research plan for its effective use. This Plan by the DRWG is the first step in this direction.
The Research PlanThe Diabetes Research Working Group is convinced that a significant investment in research today will greatly speed progress in understanding and conquering this disease and its complications. The Strategic Research Plan set forth has two overarching goals:
- Understand the causes and define approaches to prevent the development of Type 1 and Type 2 diabetes and their complications.
- Develop methods for optimal management, treatment and ultimate cure of diabetes and its complications.
The DRWG has divided this Research Plan into the following three major components, and provided specific recommendations concerning the types of efforts, budgetary requirements and program mechanisms that should be pursued to realize compelling research goals:
- Extraordinary Opportunities: Rapidly expanding, crosscutting areas in which increased investment or development of new mechanisms will significantly speed research.
- Special Needs for Special Problems: Equally important, but more focused research areas targeted to specific populations, complications, and methodological approaches.
- Resource and Infrastructural Needs: A bold plan for increasing research manpower, technology and other infrastructure elements for diabetes-related research.
Extraordinary OpportunitiesExciting and rapid research advances in recent years have opened the door to a new understanding of diabetes. The next decade offers important research opportunities that, if seized now, can vastly improve the lives of people with or at risk for diabetes. The Diabetes Research Working Group has identified five areas that offer extraordinary opportunities for making genuine and significant progress toward understanding, more effectively treating, and ultimately preventing and curing diabetes. They are: the genetics of diabetes and its complications; autoimmunity and the beta cell; cell signaling and cell regulation; obesity; and clinical research and clinical trials of critical importance.
Genetics of DiabetesBecause Type 1 and Type 2 diabetes and their complications have strong genetic determinants, defining the specific genes involved is essential to prevention and could lead to new and better therapies. Defining the genes for diabetes and its complications will also help isolate the environmental factors involved in the disease and may identify genetic factors that contribute to variations in response to medications. Thus, a major goal for the coming decade must be to identify these predisposing genes.
Although most of the basic tools for genetic studies are in place and much progress has been made, current approaches are inadequate to tackle the vital genetics questions in a reasonable time frame. Three major impediments are inadequate resources; the lack of an appropriate mechanism to bring together the groups of researchers and patient samples to conduct the necessary studies; and fragmented genetic repositories.
- Establish a National Consortium for the Study of the Genetics of Diabetes to create a strong, coordinated effort for analysis of the role of genetics in diabetes and its complications.
- Enhance research in laboratory animals and humans to discover the biochemical mechanisms by which diabetes genes function to create susceptibility to diabetes and its complications.
Autoimmunity and the Beta CellType 1 diabetes is an "autoimmune" disease in which the body’s own defense system mistakenly attacks and destroys insulin-producing beta cells of the pancreas. Important discoveries and concepts have emerged during the past decade from research in basic immunology, cell biology, and autoimmune diseases, including Type 1 diabetes. Based on this solid research foundation, the DRWG believes that aggressive pursuit of three scientific areas over the next decade could lead to dramatic improvements in diabetes therapy and prevention.
- Define the immunological basis of Type 1 diabetes and develop methods for prevention of the disease.
- Intensify research to understand the immunological basis of Type 1 diabetes.
- Complete mapping of T cell specificity of autoimmune responses to major pancreatic islet cell proteins and identify optimal strategies for immunotherapy.
- Expand the scope of efforts to identify immune response markers that reliably detect individuals predisposed to Type 1 diabetes in the population at large.
- Conduct additional clinical trials of immunoprevention of Type 1 diabetes using antigen-specific, cytokine- or antibody-based immunotherapy.
- Advance research on islet cell transplantation for treatment of diabetes.
- Establish Centers for Islet Transplantation with appropriate funding to undertake immediate clinical trials of islet transplantation in patients with Type 1 diabetes and to evaluate various methods of immune intervention.
- Support an expanded system for national collection of human pancreas for isolation and distribution of islets for clinical studies and clinical trials, and establish a Task Force to make recommendations on approaches to enhance this process.
- Develop methods to stimulate beta cell growth and regeneration.
- Increase basic research on the control and regulation of islet cell differentiation, growth and development, and devise methods for stimulating growth or regeneration of islet cells.
- Create Interdisciplinary Centers for Beta Cell Biology to expand current efforts and bring new investigators into the field. These Centers should be applicable to research efforts on both Type 1 and Type 2 diabetes.
Cell Signaling and Cell RegulationIntracellular and intercellular communication is the basic mechanism for the regulation of all cells. Disturbances in cell signaling are central to disturbances in insulin secretion and action, which lead to diabetes and to both micro- and macrovascular complications. Basic research in this area is not only essential to understanding diabetes, but is also critical to understanding many diabetes-related complications. Most importantly, this type of "discovery" research can identify important targets for new treatments. It would also complement the important new information about the genetic underpinnings of disease.
Recent progress in research on signaling systems and in the ability to use genetic methods to study these pathways has created an extraordinary opportunity to determine the exact mechanisms of signal communication and its alterations in diabetes. A parallel opportunity exists to identify the molecular events responsible for the insulin resistance characteristic of Type 2 diabetes.
The DRWG has identified five areas of opportunity in cell signaling and regulation that warrant increased research. These are: dissection of insulin and hormone signaling pathways; understanding and countering insulin resistance; defining mechanisms regulating beta cell function; metabolic staging of diabetes; and defining alterations in signaling pathways that lead to development of diabetes complications.
- Complete the dissection of hormone signaling pathways, particularly the pathways of insulin action, and define their alterations in diabetes, including insulin resistance.
- Significantly increase research in the fundamental science of cellular signaling as it relates to diabetes and its complications.
- Remove the limits currently present on research project (RO1) and program project (PO1) grants, such as budget caps, limitations on growth of programs, and considerations of average grant size, to maximize the opportunity for effective research teams to be formed.
- Establish research centers to focus on development of methods to study cellular signaling at the molecular and genetic level in humans with diabetes to allow correlation between the physiological defects and the molecular alterations.
- Expand research to identify the underlying genetic and biochemical basis of insulin resistance, and to develop interventions to prevent, reverse and ameliorate it in Type 2 diabetes and obesity.
- Define mechanisms regulating beta cell function and their alterations in Type 2 diabetes.
- Increase research on signaling pathways involved in the regulation of normal beta cell function and their derangements in diabetes.
- Use the proposed Interdisciplinary Centers for Beta-Cell Biology to study the alterations in signaling in Type 2 diabetes.
- Allow metabolic staging of diabetes and identify the mechanisms of complications.
- Develop a program of research to allow metabolic staging of Type 2 diabetes, and to detect individuals at high risk for this form of the disease and its complications.
- Expand support of interdisciplinary research to identify the mechanisms of the complications of diabetes, including interactive mechanisms and program project grants, which bring together investigators with different areas of expertise.
Obesity–Critical in Diabetes and a Major Problem of Its OwnObesity is a major risk factor for the development of Type 2 diabetes and insulin resistance, as well as a major cause of morbidity and mortality in the U.S. One of every two Americans is overweight, and the prevalence has increased 30 percent in the past decade alone. Obesity disproportionately affects minorities. Over 60 percent of African American, Mexican American, and Native American women meet the criteria of being overweight and between 33 and 37 percent are obese. Moreover, obesity in children and adolescents is increasing at alarming rates, leading to occurrence of Type 2 diabetes in these groups.
Obesity results from an imbalance between energy intake and energy expenditure. The recent discovery of the fat cell hormone, leptin, and other appetite-regulating hormones has demonstrated that certain types of obesity are not simply due to overeating, but are the result of misregulated pathways that control the balance between appetite and energy expenditure. These new discoveries have provided a revolutionary understanding of obesity at the molecular level, thus leading to extraordinary opportunities in biomedical and behavioral research.
- Increase the size, scope, number and funding level of NIH sponsored Obesity Research Centers to meet appropriately the severity of this problem in the U.S.
- Significantly increase research in the basic sciences underlying obesity to capitalize on recent advances in hormonal control of appetite, energy regulation, metabolism, and adipocyte development.
- Develop stronger industry-NIH relationships to support obesity-related research.
- Enhance behavioral research in obesity.
Clinical Research and Clinical Trials of Critical ImportanceTranslation of basic research into human therapies depends on an active and vigorous clinical research program. Studies in test tubes, cells and animals can answer questions of fundamental importance, and often provide the basis for development and initial testing of potential interventions. However, it is clinical studies in patients with diabetes that are essential for validating these observations and their relevance to human disease. In addition, clinical studies give key insights into the genetic, immune, hormonal, metabolic and environmental factors involved in the disease, and allow true testing of therapeutic strategies. Several prevailing forces, however, have significantly hampered clinical research and clinical trials in diabetes. Investigator-initiated clinical research is decreasing as a result of decreasing numbers of clinical investigators, limitations on funding of clinical research, the high cost of clinical research, and the complexity of clinical challenges. A major factor hampering clinical trials is the lack of infrastructure to organize and support them.
For diabetes, the long-term nature of the complications adds to the complexity of clinical trials. In most clinical studies, it is difficult to have adequate representation of high-risk minority groups due to the ad hoc nature of the organization of clinical trials. For robust and effective clinical research, additional well-trained clinical investigators and increased funding of meritorious clinical studies are required. Also needed are efficient systems for clinical research to provide the necessary numbers of patients and the stability of operations for long-term studies, and opportunities to include sufficient numbers of appropriate minority groups.
A comprehensive program for tackling a major public health problem such as diabetes requires a major investment, not only in basic research, but also in clinical research and clinical trials. The latter are particularly needed to document the safety and efficacy of various therapeutic strategies and generate the knowledge base for "evidence based medicine" that will lead to better treatment of diseases. There are two major needs to achieve these goals. The first is creation of an infrastructure to facilitate clinical trials—both improving efficiency and lowering cost. This need is especially apparent in diabetes where clinical trials to "hard endpoints" may take many years and even decades. The second need is a commitment to using clinical trials as a mechanism to develop the proper base of knowledge and to assure steady improvement in the care of people with diabetes.
- Establish a national diabetes trial network (Diabetes TrialNet) of cooperative clinical research groups to create the stable, high-quality infrastructure necessary for the conduct of effective and efficient clinical trials in diabetes.
- In addition, the Diabetes Research Working Group recommends that NIH:
- Increase funding of meritorious clinical trials of emerging new therapies for diabetes and its complications.
- Support critical trials on how to most effectively apply the current methods of therapy and identify new, more generally applicable methods for achieving tight blood glucose control without hypoglycemia.
- Support clinical trials on the prevention of microvascular and macrovascular disease, the major causes of morbidity and death in people with diabetes.
- Develop effective partnerships among the NIH, academia and industry for collaboration and co-funding of clinical trials in diabetes and to provide training in the science of clinical trials.
- Increase funding of meritorious clinical research for physiological studies and development of new technologies for metabolic assessment. These should include efforts to:
- Initiate clinical studies of promising new therapies for diabetes, such as gene therapy, or tissue-specific approaches to microvascular complications.
- Initiate studies to determine the reasons that women and some minority populations with diabetes have higher risks for diabetic complications.
- Increase opportunities for and support of clinical research training in diabetes.
- Perform clinical studies to establish and validate surrogate endpoints for the complications of diabetes to be used in clinical research and clinical trials.
Special Needs for Special ProblemsMicro- and Macrovascular Complications
The different types of diabetes and the array of complications they present offer a wide range of specific research needs unique to each. The micro- and macrovascular complications of diabetes are responsible for most of the morbidity and mortality in both Type 1 and Type 2 diabetes. Their prevention and reversal will greatly reduce the burden of this disease on individuals and on the nation. Understanding and combating the complications of diabetes will require significantly expanded research in mechanisms involved in the development and progression of the complications of diabetes. Several promising research avenues must be pursued through intensified basic and clinical research. This will require an increased effort from the existing community of scientists working in diabetes, as well as important new input from scientists in immunology, genetics, neurology, atherosclerosis, obesity and maternal and child health.
Recommendations on Diabetic Kidney Disease:
- Increase the study of the basic mechanisms involved in diabetic nephropathy, including studies of extracellular matrix, growth factors, cytokines and genetic factors, and develop strategies to prevent and reverse this process.
- Initiate clinical studies to establish and validate additional markers for staging of disease and use in clinical trials on diabetic nephropathy, including functional imaging and other minimally invasive approaches.
- Establish multidisciplinary centers for the study of diabetic nephropathy in order to expand basic and clinical research studies and identify leads for prevention and treatment.
Recommendations on Diabetic Eye Disease:
- Increase basic and clinical research on the role of hormones, growth factors and other molecules in the development and progression of diabetic retinopathy.
- Increase research into the potential for tissue-specific gene therapy and drug delivery, including approaches for regeneration and rescue of retinal function.
- Increase basic and clinical research to develop and improve prosthetics and transplantation technology for diabetic retinopathy.
Recommendations on Diabetic Nerve Disease:
- Significantly increase the investment in fundamental research to determine the mechanisms of the nerve damage in diabetes, to expand research on nerve regeneration and rescue, and to evaluate methods to enhance peripheral and autonomic function.
- Initiate clinical studies to establish and validate surrogate markers for use in clinical trials on diabetic neuropathy, including new technologies that will aid in the measurement and evaluation of nerve function in people with diabetes.
- Establish new multidisciplinary centers for the study of metabolic nerve diseases, with an emphasis on diabetic neuropathy, to develop leads for prevention and treatment.
Recommendations on Macrovascular Complications:
- Increase research on the mechanisms by which diabetes and insulin resistance enhance the atherosclerotic process and on the mechanisms of angiogenesis and its use in the treatment and prevention of macrovascular disease.
- Increase research to determine the mechanisms responsible for the loss of the vascular-protective effect in premenopausal women.
- Increase basic and clinical research to study myocardial function and the cardiac and micrometabolic environment in diabetic heart disease in order to identify the mechanisms that lead to the high mortality in the peri-infarction period and in patients undergoing surgery, and to develop effective preventive interventions.
- Support research to develop appropriate animal models of diabetes and atherosclerosis.
- Support further analysis of existing studies and new clinical research to identify the presence, predict the progression, and assess the response to therapy of macrovascular complications in patients with diabetes.
- Create multidisciplinary Centers for Diabetes and Vascular Disease.
Methods to Optimize Glucose ControlDespite the findings of clinical trials and other studies that have demonstrated the importance of tight glucose control to minimize the risk of long-term complications, many patients continue to have far less than optimal control. This is due in part to the risk of hypoglycemia, which increases with intensified therapy, and in part to the difficulty of obtaining optimal control in a general clinical setting. The Diabetes Research Working Group believes that identification of methods that promote implementation of these standards of treatment should be a high priority of current clinical research.
- Increase basic and clinical research to discover novel approaches for controlling hyperglycemia in diabetes. These approaches should include designing small, orally bioavailable molecules mimicking insulin action; overcoming insulin resistance or stimulating insulin secretion in a physiologic manner; and developing technologies that enable administration of insulin by routes other than injection. This research could involve enhanced collaboration with the pharmaceutical and biotechnology industry.
- Develop a focused, multi-disciplinary research program on hypoglycemia and hypoglycemic unawareness. This research should include the neuroendocrine and neuroscience mechanisms that underlie these problems, and increased clinical research to find simple, reliable techniques to identify patients at greatest risk for severe hypoglycemia.
- Initiate immediate review of the research program to develop mechanical approaches to insulin replacement by the Diabetes Technology Taskforce (see "Resource and Infrastructural Needs").
Diabetes and the EnvironmentThe environment appears to play important roles in Type 1 diabetes as a trigger for the autoimmune response and in Type 2 diabetes as a modifier of pre-existing genetic risk. While the latter influence is partly understood, but difficult to control, the former influence has been difficult to define in any specific way. Identification of these environmental factors would provide important information for any preventive strategies for either form of diabetes.
- Hold a series of conferences and workshops to explore new methods to search for the environmental triggers of Type 1 diabetes and other autoimmune diseases.
- Perform epidemiologic analysis of suspected triggering factors, such as latent or endogenous viruses (including retroviruses) or other substances, whose activation may initiate the autoimmune process.
- Explore with the Centers for Disease Control and Prevention the possibility of a national registry for Type 1 diabetes as a mechanism to enhance epidemiologic research.
- Support research to develop and apply new technologies to provide accurate, affordable, quantitative measures in normal, living humans of individual-specific energy expenditure, energy intake and macronutrient composition, which contribute to obesity and Type 2 diabetes.
- Initiate new epidemiological studies taking into account genetic susceptibility to help identify additional environmental risk factors for Type 2 diabetes, such as stress levels and bacterial/viral infectious agents.
- Study environmental factors responsible for the increase in Type 2 diabetes in children and ways to modify them.
Diabetes in Women, Children and the ElderlyDiabetes mellitus presents additional problems to women with its impact on reproductive health and vascular complications. Children and the elderly present special problems in management and may have additional physiological variables that must be addressed through specific research.
- Increase basic and clinical research to identify the mechanisms by which the intrauterine environment, including the diabetic environment, affects the immediate and long-term health outcomes for children and their risks of diabetes and obesity.
- Support research to determine the impact of Type 1 and Type 2 diabetes on women, including their reproductive health; risk of cardiovascular disease; the relationship of insulin resistance syndrome and polycystic ovarian disease; and the risk of diabetes following gestational diabetes mellitus.
- Increase studies about specific psychosocial issues that face women, children and the elderly with diabetes, including eating disorders, impact of school settings on diabetes, and the management of diabetes in assisted-living situations.
- Increase studies of how to implement effectively the principles of the Diabetes Control and Complications Trial (DCCT) in children with Type 1 diabetes in an effort to improve glucose control and reduce the complications of disease.
- Increase studies on age-related changes in the development of Type 2 diabetes, and the effects of these changes on responses to treatment and prevention strategies in older persons.
Diabetes in Minority PopulationsMinority populations, including African Americans, Hispanics, Native Americans, and Asians, have the highest incidence of diabetes and the highest rates of complications of the disease. Current research has only begun to address the reasons for this in a very limited way. These groups are rapidly growing segments of the population and specific research must address the reasons for the disproportionate impact of diabetes they bear.
- Increase efforts in genetic studies in minority populations as part of the proposed National Consortium for the Study of Genetics of Diabetes.
- Support research to identify physiologic and environmental determinants for development of Type 2 diabetes and its complications in minority populations, including in children and adolescents.
- Support research to identify risk factors, co-morbidities, and primary and secondary prevention strategies for micro- and macrovascular complications of diabetes in minority populations.
- Initiate research to develop culturally sensitive, preventive and therapeutic approaches utilizing appropriate, innovative communication and education techniques applicable in relevant, "real world" settings, for example, rural clinics, county clinics, and urban health centers.
- Design and conduct studies in partnership with minority communities to understand more fully the cultural, familial, and other factors that influence adoption of health-promotion, and to change high risk behaviors in those with or at risk for Type 2 diabetes.
Genetic EngineeringThe ability to modify the function of cells through genetic engineering opens up tremendous opportunities for new therapeutic approaches to diabetes and its complications. The Diabetes Research Working Group recommends that several applications of this technology be explored.
- Increase research to explore the possible use of genetic engineering as a strategy for beta-cell replacement and immunomodulation of transplanted cell lines.
- Expand research to explore the potential for gene therapy for Type 2 diabetes.
- Bolster research to explore unique applications of gene therapy for tissue-specific approaches to micro- and macrovascular complications.
Behavioral and Health Services ResearchLifestyle variables, such as dietary intake and physical activity, represent important risk factors for Type 2 diabetes. Type 1 diabetes management can also be influenced by behavioral patterns and can greatly influence personal, family and social dynamics.
- Intensify clinical behavioral research to develop interventions to improve patients’ adherence to diabetes treatment and their quality of life, and promote sustained improvements in lifestyle behaviors, particularly diet and exercise, which will effectively prevent and reduce the risk for diabetes.
- Extend research and development of valid methodologies to measure psychosocial and behavioral factors in diabetes.
Magnitude of the ProblemThe magnitude of the problem created by diabetes is clearly defined by a few simple facts:
- Diabetes currently affects an estimated 16 million Americans, and about 800,000 new cases are diagnosed each year.
- Diabetes spares no group—attacking men, women, children, the elderly and people from every racial background.
- African, Hispanic, Native and Asian Americans, some of the fastest growing segments of the U.S. population, are particularly vulnerable to diabetes and its most severe complications.
- Diabetes strikes both ends of the age continuum. Children and young adults with Type 1 diabetes face a lifetime of daily insulin injections and the possibility of early complications whose severity will likely increase with duration. Elderly diabetics are frequently debilitated by multiple complications. Diabetes affects virtually every tissue of the body with long term and severe damage.
- Diabetic eye disease (retinopathy) is the most common cause of blindness in working age adults.
- Diabetic kidney disease (nephropathy) accounts for 42 percent of new cases of end-stage renal disease, and is the fastest growing cause of kidney dialysis and transplantation (over 100,000 cases per year).
- Nervous system damage (neuropathy) affects over 60 percent of diabetics, causing impaired sensation or pain in the feet or hands, slowed digestion of food in the stomach, impotence, and other problems.
- More than half of lower limb amputations in the United States occur among people with diabetes. From 1993 to 1995, about 80,000 amputations were performed each year on people with diabetes.
- Heart disease death rates in adults with diabetes are about 2 to 4 times those of people without diabetes. Premenopausal women lose their protection from heart disease and have even more markedly increased risk.
- High blood pressure affects over 60 percent of people with diabetes. As a result of the combination of hypertension and diabetes the risk of stroke is increased 2 to 4 times.
- Pregnancy related problems confront diabetic women. The rate of major congenital malformations and death of the fetus and newborn are increased 3 to 4 times.
- Higher rates of infection, periodontal disease, and many other problems occur in people with diabetes. Diabetes is the sixth leading cause of death due to disease in the U.S., and the third leading cause in some minority groups.
- Since 1980, the age-adjusted death rate due to diabetes has increased by 30 percent while the death rate has fallen for other common multifactorial diseases, such as cardiovascular disease and stroke.
- Life expectancy of people with diabetes averages 10 to 15 years less than that in the general population. The economic impact of diabetes is staggering.
- The cost of diabetes to the nation is over $105 billion annually.
- More than one of every ten U.S. healthcare dollars is spent for diabetes.
- One of about four Medicare dollars pays for health care of people with diabetes.
The Federal Investment in Diabetes ResearchRepresents about 3 cents out of each dollar, that is about 3 percent of the NIH research budget. Although there is no accepted method for determining appropriate levels of research funding, this is clearly a small investment for a disease that affects 6 to 7 percent of the population and accounts for more than 10 percent of all health care dollars.
- The proportion devoted to diabetes research, relative to the whole NIH budget, has decreased by more than 30 percent since 1981, at a time when the death rate due to diabetes has increased by 30 percent.
- Represents only about $30 per person affected with diabetes per year--less than two people might spend for a movie and a pizza.
Summary of Budget Recommendations
(in millions of dollars)
Extraordinary Opportunities Genetics of Diabetes 40.5 72.0 85.0 99.0 101.0 Autoimmunity and the Beta Cell 30.0 45.0 58.0 66.0 79.0 Cell Signaling and Cell Regulation 38.0 57.0 73.0 86.0 94.0 Obesity 15.0 25.0 37.0 46.0 52.0 Clinical Research and Clinical Trials 87.0 139.0 191.0 252.0 280.0 Sub-Total 210.5 338.0 444.0 549.0 606.0 Special Needs for Special Problems Microvascular Complications 51.0 80.0 106.5 124.0 129.5 Macrovascular Complications 34.0 58.0 79.0 95.0 102.0 Optimization of Glucose Control 9.5 16.0 24.0 29.0 36.0 Diabetes and the Environment 3.0 4.0 6.0 8.0 10.0 Special Needs in Women, Children and the Elderly 20.0 40.0 60.0 80.0 80.0 Special Needs in Minority Populations 9.0 15.0 22.5 30.0 32.0 Genetic Engineering 8.0 15.0 22.0 28.0 35.0 Behavioral and Health Services Research 8.0 13.5 20.0 27.0 40.0 Oral Complications of Diabetes 1.0 1.5 2.0 2.5 3.0 Sub-Total 143.5 243.0 342.0 423.5 467.5 Resource and Infrastructural Needs Research Training and Manpower Development 3.0 5.0 8.0 10.0 10.0 Diabetes Research Centers Program 6.0 15.0 25.0 40.0 40.0 Technology Taskforce 13.0 17.0 21.0 13.0 13.0 Regional Centers for Animal Models 5.0 10.0 16.0 26.0 26.0 Human Material for Diabetes Research 2.0 2.0 2.0 2.0 2.0 NIH-Pharmaceutical and Biotechnology Interactions 0.5 0.5 0.5 0.5 0.5 Review of Intramural Programs of NIH 0.5 0.5 0.5 0.5 0.5 Taskforce for Strategic Planning 0.5 0.5 0.5 0.5 0.5 Sub-Total 30.5 50.5 73.5 92.5 92.5 Increment over FY99 Base to Implement
Recommendations in DRWG Strategic Research Plan
384.5 631.5 859.5 1065.0 1166.0 FY99 Base for Diabetes Research 442.8 442.8 442.8 442.8 442.8 Grand Total for Diabetes Research 827.3 1074.3 1302.3 1507.8 1608.8
More detailed budgetary information presented in terms of the specific scientific recommendations and the corresponding additional funds proposed for individual Institutes and Centers of the National Institutes of Health will be found in the full Strategic Plan of the Diabetes Research Working Group.
Diabetes Research Working Group
C. Ronald Kahn, M.D., Chairman
Director, Joslin Diabetes Center
Mary K. Iacocca Professor of Medicine
Harvard Medical School
Jose Caro, M.D.
Lilly Research Laboratories
Nancy Cox, Ph.D.
University of Chicago
National Disease Research Interchange/
Human Biological Data Interchange
Joyce C. Dugan
Eastern Band of Cherokee Indians
Robert N. Frank, M.D.
Wayne State University School of Medicine
James R. Gavin III, M.D., Ph.D.
Howard Hughes Medical Institute
Willa Ann Hsueh, M.D.
University of California, Los Angeles
Hugh O. McDevitt, M.D.
Douglas Melton, Ph.D.
Christopher B. Newgard, Ph.D.
University of Texas SW Medical Center
Daniel Porte, Jr., M.D.
University of Washington and
Seattle Veterans Affairs Medical Center
American Diabetes Association
Juvenile Diabetes Foundation International
Michael P. Stern, M.D.
University of Texas Health Science Center at San Antonio
Rena Wing, Ph.D.
University of Pittsburgh School of Medicine and
Lester B. Salans, M.D.
LBS Associates, New York, served as Senior Medical Advisor.
Ad Hoc Consultants to the Congressionally-Established Diabetes Research Working Group
Kelly J. Acton, M.D., M.P.H., F.A.C.P.
Indian Health Service
Michael A. Brownlee, M.D.
Albert Einstein College of Medicine
Thomas A. Buchanan, M.D.
University of Southern California School of Medicine
Patrick Concannon, Ph.D.
University of Washington
Donald Coustan, M.D.
Brown University School of Medicine
George S. Eisenbarth, M.D., Ph.D.
University of Colorado Health Sciences Center
Edwin Fisher, Ph.D.
Michael S. German, M.D.
University of California - San Francisco
Marvin C. Gershengorn, M.D.
Cornell University Medical College
Daryl K. Granner, M.D.
Vanderbilt University School of Medicine
Thomas C. Hohman, Ph.D.
George L. King, M.D.
John Kitzmiller, M.D.
Good Samaritan Hospital
S. Robert Levine, M.D.
Juvenile Diabetes Foundation International
Michael Mauer, M.D.
University of Minnesota Medical School
Boyd E. Metzger, M.D.
Richard Nesto, M.D.
New England Deaconess Medical Center
Jerrold M. Olefsky, M.D.
University of California, San Diego
Jeffrey E. Pessin, Ph.D.
University of Iowa
Kenneth S. Polonsky, M.D.
The University of Chicago
E. Albert Reece, M.D.
Temple University School of Medicine
Douglas L. Rothman, M.D., Ph.D.
Yale University School of Medicine
Christopher D. Saudek, M.D.
Johns Hopkins University
Gerald I. Shulman, M.D., Ph.D.
Yale University School of Medicine
Anders A.F. Sima, M.D., Ph.D.
Wayne State University School of Medicine
Indian Health Service Diabetes Program
Additional copies of this document may be obtained from:
National Diabetes Information Clearinghouse
1 Information Way
Bethesda, MD 20892-3560
Posted 28 February 1999
Last Updated: Thursday February 27, 2014 19:28:21
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2017. Comments and Feedback.